Skip to content

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06203249
Enrollment
50
Registered
2024-01-12
Start date
2024-01-20
Completion date
2026-11-25
Last updated
2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-MDA5 Antibody Positive Dermatomyositis, Immune Function, Microbiome

Brief summary

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Detailed description

Methods: Bronchoalveolar lavage specimens of patients with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.

Interventions

None listed

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive. * Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD. * Must have undergone bronchoalveolar lavage. * Age≥18 years old. * Patients who signed informed consent forms

Exclusion criteria

* Patients who had other connective tissue diseases. * Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors. * Pregnant or lactating patients. * The patient also participated in any other clinical trial. * Disagreement for inclusion in this study

Design outcomes

Primary

MeasureTime frameDescription
The relationship between the microbial community and the presence or absence of interstitial lung disease6 monthsThe relationship between the microbial community and the presence or absence of interstitial lung disease

Countries

China

Contacts

Primary ContactZhimei Duan, doctor
549117002@qq.com13716376758

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026